JPM | Free Full-Text | Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Look at the Approved and Emerging Therapies
Diffuse Large B-Cell Lymphoma | NEJM
Targeting the B-cell receptor pathway in diffuse large B-cell lymphoma. | Semantic Scholar
NIH study revises molecular classification for most common type of lymphoma | National Institutes of Health (NIH)
PDF) Ibrutinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Retrospective Study
Ibrutinib improves survival for younger people with diffuse large B-cell lymphoma
Ibrutinib, rituximab, and lenalidomide in unfit or frail patients aged 75 years or older with de novo diffuse large B-cell lymphoma: a phase 2, single-arm study - The Lancet Healthy Longevity
Frontiers | The path towards consensus genome classification of diffuse large B-cell lymphoma for use in clinical practice
Overall survival following Richter transformation on ibrutinib by line... | Download Scientific Diagram
Resistance to BTK inhibition by ibrutinib can be overcome by preventing FOXO3a nuclear export and PI3K/AKT activation in B-cell lymphoid malignancies | Cell Death & Disease
miR-28-based combination therapy impairs aggressive B cell lymphoma growth by rewiring DNA replication | Cell Death & Disease
Cancers | Free Full-Text | Regulation of B-Cell Receptor Signaling and Its Therapeutic Relevance in Aggressive B-Cell Lymphomas
The clinical picture of primary cutaneous diffuse large B-cell... | Download Scientific Diagram
JCI Insight - Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265P mutations
Ibrutinib Boosts Survival in Younger Patients With Certain DLBCL Subtypes | MedPage Today
Ibrutinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Retrospective Study | Indian Journal of Hematology and Blood Transfusion
Combination of Enzastaurin and Ibrutinib synergistically induces anti-tumor effects in diffuse large B cell lymphoma | Journal of Experimental & Clinical Cancer Research | Full Text
News on Diffuse Large B-Cell Lymphoma » Coping with Cancer
Ibrutinib, rituximab, and lenalidomide in unfit or frail patients aged 75 years or older with de novo diffuse large B-cell lymphoma: a phase 2, single-arm study - The Lancet Healthy Longevity
JCI - Pharmacoproteomics identifies combinatorial therapy targets for diffuse large B cell lymphoma
Ibrutinib Monotherapy in Relapsed or Refractory, Transformed Diffuse Large B -cell Lymphoma - ScienceDirect
Ibrutinib improves survival in young people with diffuse large B-cell lymphoma
PDGFD induces ibrutinib resistance of diffuse large B‑cell lymphoma through activation of EGFR
